French Innovative Leukemia Organisation

This study looks at whether older, frail patients with untreated chronic lymphocytic leukemia (CLL) can safely stop taking the targeted drug acalabrutinib after 18 months and then restart it if their disease comes back. The goal is to reduce long-term side effects and the risk of…

This phase 2 pilot study is testing whether combining two drugs, ibrutinib and daratumumab, can improve outcomes for people with relapsed or refractory chronic lymphocytic leukemia (CLL) that has a p53 gene problem. The 29 participants will take ibrutinib daily and receive daratu…

This phase II trial tests the drug venetoclax as an early treatment for people with high-risk chronic lymphocytic leukemia (CLL) that hasn't caused symptoms yet. About 82 participants will take venetoclax daily for up to 18 months. The goal is to see if the drug can wipe out near…

This study follows 1,000 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in France to see how they are actually treated in everyday clinics, not just in controlled trials. Researchers will track which therapies patients receive, in what order, a…